In addition, molecular interactions between MET and ERBB receptor family signaling pathways may lead to resistance of breast cancer to HER2- and EGFR-targeted therapies [69], implying that MET is promising for the development of oncodriver-targeted therapies. This evidence concerns the gene EGFR and breast carcinoma.